Chief, Section on Medical Neuroendocrinology
NIH
Bethesda, Maryland, United States
Dr. Karel Pacak is an endocrinologist and tenured Chief of the Section on Medical Neuroendocrinology at Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), NIH, Bethesda, MD. He graduated summa cum laude from Charles University in Prague, Czech Republic, where he received his medical and scientific degrees. He is recognized nationally and internationally for patient-oriented pheochromocytoma (PHEO) and paraganglioma (PGL) research programs. He and his colleagues described the role of a new HIF2A gain-of-function somatic mutation in the pathogenesis of paraganglioma, somatostatinoma, and polycythemia (a new syndrome now known as the Pacak-Zhuang syndrome). He and his colleagues also discovered other genes including SUCLG2, PHD1, and IRP1 in the pathogenesis of PHEO/PGL. He and his colleagues introduced into clinical practice genotype-specific functional imaging approaches for PHEO/PGL. He and his colleagues introduced PARP inhibitors with temozolomide and ascorbic acid as potential treatment options in metastatic PHEO/PGL. Apart from but in line with his life’s work, Dr. Pacak has skillfully applied his knowledge for the benefit of the greater good. He established a new series of international pheochromocytoma conferences (ISP), for which he has served as the president and principal organizer of the first conference in 2005 and 2022. He has received distinguished awards from the International Association of Endocrine Surgeons, Australian Endocrine Society, Irish Endocrine Society, the Outstanding Clinical Endocrinologist Award and Frontiers in Science and Distinction in Endocrinology Award from AACE, the Outstanding Clinical Investigator Award from the US Endocrine Society, the Gold Jessenius Medal from the Slovak Academy of Sciences, Purkyne Medal from the Czech Medical Society, and the Directors’ award from the NIH and NICHD. He published over 700 peer-reviewed articles.
Disclosure information not submitted.
Saturday, May 11, 2024
10:45 AM – 12:00 PM CDT